Cochrane Review Group

Kidney and Transplant

139 systematic reviews in Kidney and Transplant ask 2,434 questions. 20.7% have no studies to answer them, 25.1% rest on very low certainty evidence and 20.1% reach moderate or high certainty.

Reviews

139

Questions

2,434

current versions

No studies

20.7%

Moderate or high

20.1%

No studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Kidney and Transplant

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Valaciclovir vs ganciclovir or valganciclovir Acute rejection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	RR 0.91 [0.22, 3.73]	3 studies · 271 participants	Very low
Low vs standard dose valganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Low vs standard dose valganciclovir Adverse events · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Graft loss · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Maribavir vs ganciclovir Opportunistic infection · solid organ transplant recipients Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs placebo or no treatment Death (any cause) · people with IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Remission of haematuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Renin‐angiotensin system inhibition vs other supportive care treatment Relapse of proteinuria · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Death (any cause) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Kidney failure · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	no estimate extracted	NR	No studies
Tonsillectomy plus standard care vs standard care Relapse of haematuria (macroscopic) · people IgA nephropathy Non‐immunosuppressive treatment for IgA nephropathy (2024) · Cochrane	RR 1.33 [0.8, 2.23]	1 study · 32 participants	Very low

Reviews 139

Steroid avoidance or withdrawal for kidney transplant recipients

Haller, MC, Royuela, A, et al. · Cochrane Database of Systematic Reviews · 2016

Kidney and Transplant

Thinnest evidence

Reviews 139

Steroid avoidance or withdrawal for kidney transplant recipients

Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units

Acupuncture and related interventions for symptoms of chronic kidney disease

Intensity of continuous renal replacement therapy for acute kidney injury

Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections

Pre‐emptive correction for haemodialysis arteriovenous access stenosis

Haemodiafiltration, haemofiltration and haemodialysis for end‐stage kidney disease

Bicarbonate‐ versus lactate‐buffered solutions for acute continuous haemodiafiltration or haemofiltration

Preoperative vascular access evaluation for haemodialysis patients

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients

Probiotics for preventing urinary tract infections in adults and children

Antibiotics for asymptomatic bacteriuria

Dietary interventions for mineral and bone disorder in people with chronic kidney disease

Chinese herbal medicine for treating recurrent urinary tract infections in women

HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass

Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function

Antibiotics for acute pyelonephritis in children

Frequency of administration of erythropoiesis‐stimulating agents for the anaemia of end‐stage kidney disease in dialysis patients

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

Androgens for the anaemia of chronic kidney disease in adults

Astragalus (a traditional Chinese medicine) for treating chronic kidney disease

Continuous renal replacement therapy (CRRT) for rhabdomyolysis

Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis

Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients